Open an account

Collplant Biotechnologies

CLGN · NASDAQ

$3.88+$0.00 (+0.00%)TodayMarket closed ·
Prev close $3.88

About CLGN

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 39 full-time employees. The firm provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

Employees
39
Headquarters
Rehovot, Central(HaMerkaz)
Listed
Sep 1, 1993
Sector
Health Care
Industry
Biotechnology
Website
collplant.com

CLGN key statistics

Market cap
7.34M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
56.90K
Volume
1
Open price
$3.68
High today
$3.88
Low today
$3.53
52 Week high
$26.80
52 Week low
$2.64

Collplant Biotechnologies (CLGN) at a glance

As of Oct 21, 2026, Collplant Biotechnologies (CLGN) shares are priced at $3.88, giving the company a market cap of 7.34M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.53 and $3.88. The current price is 9.9% above the day's low and 0.0% below its high.

Volume so far is 1 shares, below the average of 56.90K shares a day.

Over the past year Collplant Biotechnologies has ranged from $2.64 to $26.80, and now sits 5% of the way up that range.

Collplant Biotechnologies met or beat analyst EPS estimates in 0 of the last 8 quarters. In Q4 FY25 it reported -$2.60 per share against an estimate of -$1.94.

The average analyst price target is $11.22, 189.2% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $11.22
Low
$11.11
Now
$3.88
High
$11.55

CLGN earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 8 quarters.

  1. Q1 FY24: reported -$0.37 per share against an estimate of -$0.357
  2. Q2 FY24: reported -$0.37 per share against an estimate of -$0.2754
  3. Q3 FY24: reported -$0.38 per share against an estimate of -$0.2907
  4. Q4 FY24: reported -$0.34 per share against an estimate of -$0.2805
  5. Q1 FY25: reported -$0.13 per share against an estimate of -$0.0408
  6. Q2 FY25: reported -$0.28 per share against an estimate of -$0.1428
  7. Q3 FY25: reported -$0.27 per share against an estimate of $0.1581
  8. Q4 FY25: reported -$2.60 per share against an estimate of -$1.94

CLGN news

  • Press releasePRNewswire

    COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT

  • Press releasePRNewswire

    LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations

  • Press releasePRNewswire

    COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

  • Press releasePRNewswire

    LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads

  • Press releasePRNewswire

    CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement

  • Press releasePRNewswire

    CollPlant to Host LightSolver Investor Webinar on September 17, 2026

  • Press releasePRNewswire

    COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION

  • Press releasePRNewswire

    COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR

Similar companies

Companies in the same industry as Collplant Biotechnologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.